Overall survival and recurrence rates aft er liver transplantation (LT) for hepatocellular carcinoma (HCC) vary, however observational data support the notion that patients with HCC have an overall worse long-term prognosis aft er LT compared to patients transplanted without HCC. Patient selection for LT in patients with HCC fl uctuated as changes in the model for end-stage liver disease score was adjusted from 2002 to 2005. In the last decade, management of HCC patients on the waiting list has varied based on center experience. Since HCC patients have better access to the donor pool compared to non-HCC patients as evidenced by their lower dropout rate from the waiting list, living donation has been implemented in certain centers. Overall patient survival, recurrence free survival, and recurrence rates have been compared between living donor LT (LDLT) and deceased donor LT, with one meta-analysis reporting a lower disease free survival in LDLT, however overall patient survival and recurrence rates showed no diff erence at 1, 3 and 5 years. In patients exhibiting HCC recurrence, diff erent modalities regarding immunosuppression and therapies have been evaluated. Currently there are no consensus treatment strategies regarding post-transplant HCC recurrence in patients not suitable for locoregional therapy, hence consideration of a mammalian target of rapamycin inhibitors with the addition of sorafenib might be a feasible option with close monitoring in clinical practice despite the notable toxicities.
Introduction
Hepatocellular carcinoma (HCC) is a major health concern worldwide, resulting from chronic liver injury and infl ammation due to viral, non-viral and genetic etiologies. HCC has been found to be the second [1] or third [2] leading cause of cancer-related death worldwide, with the majority of cases occurring in the setting of cirrhosis [3] . As the epidemic of nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis C virus continues to increase in the United States [2] , HCC rates will rise accordingly. Prior to the model for endstage liver disease (MELD) and HCC exception allocation system, patients with HCC remained on the waiting list longer than candidates without HCC, resulting in fewer than 5% of liver transplantation (LT) being performed for HCC. However, once MELD and HCC exceptions were adopted at the national level, the number of overall transplant recipients steadily increased from nearly 5,000 patients in 2002, to 6,069 patients in 2008, while HCC patients receiving LT steadily rose (from nearly 1,000 in 2002 to 1,656 in 2008) , representing over 21% of liver transplants [4] (Fig. 1) .
In February 2002, patients with HCC were given transplant exception MELD scores at higher values for both T1 and T2 lesions, based on a 3-month mortality estimate in comparison to disease progression that would preclude LT [5] . Later, followup data indicated that these exception scores were too liberal for HCC, hence adjustments in the MELD exception prioritization scheme changed over time [6] (Table 1 ). In particular, half of the patients with T1 tumor criteria (one single lesion <2 cm) were discovered not to have HCC in the explanted liver [7] . As a result, HCC patients with T1 tumors do not receive MELD exception points for HCC. However, patients within T2 criteria (1 lesion ≤5 cm or two or three lesions ≥1 cm but ≤3 cm in size) received 22 MELD exception points. In addition, patients receive additional MELD exception points every 90 days representing a 10% increase in mortality [6] . To receive these exception points, patients must be restaged every 90 days with cross-sectional imaging of the abdomen and chest to ensure that these criteria continue to be met.
Prior to 1996, restrictions on LT for HCC were more liberal, which resulted in 5-year overall survivals (OS) up to 50%. During that same year, Mazzaferro and colleagues introduced the Milan criteria (any solitary HCC ≤5 cm, or up to three lesions ≤3 cm each, without vascular invasion or metastasis) which resulted in 5-year transplant survival near 70%, with recurrence seen in less than 10% [8] . Th e importance of these independent prognostic factors matches post-transplant survival outcomes for most other liver transplant indications. Hence, a recent international consensus conference recommended using the Milan criteria as the benchmark for selecting HCC patients for LT, and when making comparisons to other suggested expansion criteria [9] .
Patients that fall outside the Milan criteria have the potential to have ablative techniques to downsize large tumors in order to fall into the exception range for LT. Th is downstaging technique is an area of ongoing research, however, with the continued organ shortage, decisions regarding transplantation need to be considered with respect to the benefi ts regarding potential HCC patients, and balanced with the consequences for all potential liver recipients on the waiting list. Th is resulted in many attempts to expand the Milan criteria as it was considered too conservative, however, only the University of California San Francisco (UCSF) criteria (one tumor ≤6.5 cm, or three nodules with the largest ≤4.5 cm, and a total tumor diameter of ≤8 cm) have demonstrated comparable outcome data in its prospectively validated design [10, 11] .
As the donor pool has stayed relatively fi xed in size over the years [12] , increasing the MELD exception scores for HCC patients may deprive other candidates without HCC from a potential LT depending on regional variations. Although expansion of the Milan criteria has shown good outcomes in select individuals [10, 13] , it should be left up to the individual regions to come to an agreement regarding any proposal change on expanding the current Milan criteria. Caution should be taken when expanding tumor criteria as HCC recurrence post-LT is a continuum as described by the "metro-ticket" analogy [14] . Th e further distance you travel underground, you pay a higher ticket premium, which is analogous to the larger the HCC tumor, the higher price you pay for HCC recurrence post-LT. While the national MELD exception criteria are followed in most regions, some regions, namely region 4 and 5 have expanded their criteria slightly. Region 5 utilizes the UCSF criteria and region 4 uses locally derived staging criteria (one lesion ≤6 cm or up to three lesions [none larger than 5 cm] with a total tumor size of <9 cm) [13] . Th is review will discuss current concepts regarding LT in the HCC patient population.
Management and outcomes of patients with HCC on the liver transplant waiting list
Patients with a diagnosis of HCC that are within the Milan criteria, and are expected to be on the waiting list for more than a few months, are considered for locoregional treatments [radiofrequency ablation (RFA) and transarterial chemoembolization (TACE)] [15, 16] . According to the most recent national dataset, locoregional therapies are being used more frequently in patients who received a LT (Fig. 2) , albeit through a regional review board, since diff erent regions vary widely on their acceptance of such patients for transplant, while the current system does not allow patients outside Milan criteria who undergo downstaging to receive HCC exception points. As of 2008, use of TACE therapies have seen a steady rise in that nearly 75% of patients underwent this type of treatment prior to receiving a LT, as compared to a slight decline to nearly one-third of individuals having RFA therapy prior to LT (Fig. 3) . Depending on the transplant centers experience, size and location of the tumor(s), patients may benefi t from locoregional procedures in the hopes of preventing progression beyond the Milan criteria, thereby maintaining their priority on the liver transplant waiting list [17, 18] .
Although the absolute benefi t in preventing waitlist dropout rates with locoregional treatment is lacking, both patient survival (79% vs. 75%, P=0.03) and graft survival (76% vs. 71%, P=0.03) at 3 years aft er LT has shown more benefi t for HCC patients receiving ablative therapy compared to those not receiving locoregional treatment [7] . However, the authors also demonstrated the adjusted patient survival at 1 year (85% vs. 88%, P=0.003) and 3 years (74% vs. 81%, P<0.001) aft er LT were signifi cantly worse in patients with HCC compared to those without HCC respectively. Th ese therapies do not impact the actuarial wait time on the LT waiting list, however, it has been shown that patients with HCC tend to have shorter wait times with regards to non-HCC patients with comparison MELD scores of 21-30 points at 1, 2, and 3 month intervals (Fig. 4) . In turn, those with HCC have less dropout or death rates in comparison to patients without HCC that have MELD scores of ≤30 [7] . Furthermore, a detailed analysis demonstrated that once a patient is diagnosed with HCC, lower dropout rates are seen within the fi rst year across all UNOS regions in these patients compared to non-HCC patients ( Fig. 5 ) [19] . As HCC patients receive locoregional therapy in most cases, the potential to arrest tumor growth without impacting their position on the waiting list is seen as a major advantage. In fact, even if the HCC tumor is successfully ablated and the patient has no residual disease, patients are still eligible for tumor exception point upgrades every 3 months, resulting in an increase in LT priority compared to non-HCC patients. It has been suggested that an HCC priority score be implemented to allow for similar dropout and LT rates for both HCC and non-HCC patients, with the hopes of allowing equal access to LT and similar post-transplant outcomes [19] . Th e long waiting time (>2 years) for HCC in some regions in the US, namely region 5, has led to an instructive "experiment of nature. " As larger cohorts of patients with HCC have been followed aft er locoregional therapy for longer periods of time, there is a subset of patients who seem to progress very slowly with regard to HCC. Such patients are typically characterized by slow or no increase in tumor size for years aft er locoregional therapy. Since most of these patients have excellent hepatic function, their urgency for transplant is not apparent. As a result, there is a movement to allow such patients to continue to receive increased MELD score increments every 90 days, but to inactivate them when their MELD score is suffi ciently high to actually receive a transplant. In doing so, patients with no or slow tumor growth would be allowed to avoid liver transplant, thereby saving them the risk of the procedure and allowing sicker patients to have access to the limited donor pool.
Living-donor LT (LDLT) versus deceased-donor LT (DDLT)
As the need for donor livers exceeds organ availability in most countries, LDLT has been suggested as an alternative to alleviate the organ shortage and possibly allow recipient expansion criteria in patients with HCC in comparison to DDLT [20] . Th e purported advantage of LDLT in HCC patients is seemingly obvious. Patients with HCC have an urgent need for transplant and the availability of a living donor would likely shorten their time to surgery, thereby preventing disease progression which might occur while waiting for a deceased donor. Previous studies have shown confl icting results with respect to recurrence rates and OS [21] [22] [23] [24] [25] , therefore, two recent meta-analyses were completed in order to evaluate overall outcomes in LDLT versus DDLT for patients with HCC [26, 27] .
In one meta-analysis [27] , a total of 7 studies with 1310 subjects were used to compare patient survival, recurrence free survival (RFS) and recurrence rates in patients with HCC receiving a LDLT or a DDLT. In another meta-analysis [26] , a total of 16 studies were used for comparison. Th e mean time from transplant to HCC recurrence ranged from 4.6 to 38 months, with the median time from recurrence to death ranging from 6 to 30.6 months. Th e disease free survival (DFS) was signifi cantly shorter in patients receiving LDLT in 3 of 10 studies analyzed, with 3-year DFS ranging from 42-95.5% compared to 41-100% aft er DDLT. Th e overall hazard ratio (HR) was not signifi cantly diff erent when comparing cohort studies from eastern and western countries for DFS aft er LDLT vs. DDLT, however, the overall HR for DFS was 1.59 (95%CI 1.02-2.49, P=0.041) aft er LDLT when 8 cohort studies were combined. Th e HR for OS aft er LDLT compared with DDLT was 0.97 (95%CI 0.73-1.27, P=0.81). Th erefore, this meta-analysis suggests that DFS is worse aft er LDLT compared to DDLT for HCC, however reports of underlying tumor biology are limited in those undergoing a shorter wait list time observed with LDLT (Table 2) . Hence, more research is needed to determine if these observed diff erences are truly due to underlying tumor biology or study bias. Th e fi nding that there is no apparent benefi t in survival for HCC patients undergoing LDLT is somewhat surprising. Th e reasons for this are not entirely clear. However, one contributing factor may be that HCC patients selected for LDLT may have tumor characteristics associated with worse tumor biology than DDLT. Th e evidence supporting this claim is based on clinical experience as well as fi ndings in the National Institutes of Health sponsored trial, the adult-to-adult living donor liver transplant study (A2ALL) [28] . In the report from this group, there was a trend toward LDLT recipients having worse tumor characteristics. Th e selection of such patients for LDLT could lead to worse outcomes. In addition, a study from the same group showed that recipients with HCC were more than twofold likely to have their donors approved for the operation. Th is might suggest that the transplant team may be more likely to approve donors for HCC patients based on the pressure to perform the surgery in desperate patients.
Risk factors for HCC recurrence: mammalian targets of rapamycin (mTORs) after LT
HCC recurrence rates aft er LT are estimated to occur in up to 20% [9] , and occur more frequently within the fi rst 2 years [29, 30] , have limited treatment options, and result in an overall poor prognosis, with a median survival of less than 1 year [31] . Th ese recurrence rates have been shown in post-LT patients predominantly to arise based on tumor biology including poorly diff erentiated tumors and macro/ microvascular invasion [14, 32] . Some studies have suggested that immunosuppression (IS) with an mTOR inhibitor may reduce the risk of HCC recurrence post-LT [33, 34] . Th e use of mTOR inhibitors is one such strategy used for both IS and anti-proliferative/anti-angiogenic properties that inhibits cell growth and survival [35] [36] [37] . Th e reluctance to use mTOR in the early post-transplant setting could be due to poor wound healing and/or hepatic artery thrombosis [38] . In fact, sirolimus (SRL), the most widely prescribed mTOR inhibitor in LT has received two "black-box" warnings against its use in liver transplant recipients based on an increased risk of hepatic artery thrombosis and death. Despite these warnings, up to 10% of liver recipients are administered this drug by one year aft er transplant. However, these mTOR medications like SRL have been shown in multiple studies to reduce HCC recurrence rates when used as the main IS agent in patients receiving LT for HCC, even though higher rejection rates have been reported [39] [40] [41] .
In 2011, a meta-analysis was conducted to determine if using SRL based regimens as IS aft er LT improves survival and recurrence of HCC in patients that had a diagnosis of HCC pre-transplant [33, 34, 39, 40, 42] . A total of 5 controlled studies from diff erent countries (3 retrospective, 1 matched-cohort and a case-control study) included 2950 participants and found that SRL-based regimens improved overall 1-, 3-, and 5-year survival (OR 4.53, 95%CI 2.31-8.89; OR 1.97, 95% CI 1.29-3.00; OR 2.47, 95%CI 1.72-3.55),respectively, compared to SRL-free regimens. One study compared the diff erent mortality risks aft er LT using various IS protocols (Fig. 6 ) [33] and showed a signifi cant diff erence in survival in patients using SRL-based IS. Furthermore, SRL-based regimens showed an overall decrease in tumor recurrence (OR 0.42, 95%CI 0.21-0.83) compared to SRL-free regimens without any signifi cant post-transplant complications observed between the two groups.
An updated meta-analysis described outcomes in patients using SRL as the main IS agent who underwent LT for HCC [43] . Of these 5 studies [34, 39, 40, 44, 45] , 474 total patients were included in the fi nal analysis, of which 77% were male, with an average age around 56 years old, having a median follow up ranging from 18 to 49 months. Th e overall results suggest that the recurrence rate of HCC aft er LT was lower in the SRL group (5-13%) compared with patients using calcineurin inhibitors (CNIs) (17-39%) with an overall advantage in all categories for the SRL group: lower recurrence rate (OR 0.3, 95% CI 0.16-0.55, P<0.001), lower recurrence related mortality (OR 0.29, 95% CI 0.12-0.70, P=0.005), and lower overall mortality (OR=0.35, 95% CI 0.2-0.61, P<0.001) respectively. Th e overall 1-, 3-, and 5-year RFS was superior in the SRL group which ranged from 93-96%, 82-86% and 79-80%, while patients taking CNIs had worse overall RFS ranging from 70-78%, 64-65% and 54-60% during the same time frame respectively. Th e overall 1-, 3-, and 5-year OS was also much better in the SRL group (94-95%, 85%, and 80%) in comparison with the CNI group (79-83%, 66%, and 59-62%) respectively (Table 2) . Similarly, overall mortality on pooled analysis was signifi cantly lower in SRL-treated patients vs. the CNI group (OR=0.35, 95%CI 0.2-0.61, P<0.001). Although limitations exist in metaanalysis which include: non-randomized data, lack of subgroup analysis regarding patients exceeding the Milan criteria, and possible publication bias based on the diff erent weighted studies, overall SRL seems to be safe, eff ective and potentially promising regarding the OS benefi ts for LT recipients having a pre-transplant diagnosis of HCC. However, more prospective studies are needed to determine if improvements in survival are due to SRL alone, or from reduction in CNIs.
More recently, a systematic review compared everolimus (another mTOR inhibitor) and SRL with CNI use on post-LT recurrence of HCC [46] . Of the 42 studies that included 3,666 HCC LT recipients analyzed, CNI use was associated with higher rates of HCC recurrence (448/3227 or 13.8%) compared to mTORs (35/439 or 8%, P<0.001), although patients treated with CNIs had lower rates of microvascular invasion and higher proportion of HCC within Milan criteria. Th e rates of HCC recurrence did not diff er if transplanted outside of Milan criteria when comparing CNI or mTOR use, while locoregional therapy data was limited when analyzing the results. A subgroup analysis demonstrated that although patients taking everolimus had shorter follow-up data, overall HCC recurrence post-LT was less frequently observed compared to SRL use (8/196 or 4.1% vs. 23/218 or 10.5%, P=0.02). Furthermore, no data was available with respect to dosage and IS levels when mTORs were used. Of note, one major diff erence between everolimus and SRL is that data using everolimus has led to FDA approval in LT recipients aft er 30 days without a black box warning [47] . Although the present analysis of multiple studies favors the use of mTOR (everolimus >SRL) for LT in HCC patients compared to CNI use, these fi ndings need longer patient follow up and comparable cohorts in order to make similar comparisons between everolimus and SRL use before fi nal conclusions can be drawn. Furthermore, when comparing overall mTOR and CNI use, the results were not signifi cantly diff erent when RCT studies were included, hence mTOR superiority over CNI use for prevention of HCC recurrence post-LT remains controversial at this time. To answer and address the issues above, a multicenter international randomized controlled trial is underway and is estimated to be completed in 2018. Th is study will analyze 5 year follow-up data to determine if the mTOR inhibitor SRL can improve HCC RFS in LT recipients with a pre-transplant diagnosis of HCC compared to SRL-free regimens [48] . All eligible LT patients (deceased donor, split-liver, or living donors) with a histological diagnosis of HCC in the explanted liver, will be given 4-6 weeks of a CNI medication (mTOR inhibitor-free), then randomized and separated into two groups: 1) mTOR inhibitor-free IS; and 2) SRL containing IS±CNI 4-6 weeks later at a loading dose of 5 mg/day and 2 mg/day thereaft er. Steroid reduction is encouraged by 3 months in both groups post-LT with a desired trough level for SRL of 4-10 ng/mL on routine lab analysis. Patients simultaneously using mycophenolic acid prodrugs and CNIs are expected to have these medications reduced by 50% with the ideal long-term goal of SRL monotherapy in arm two. Groups will be stratifi ed into high (extending beyond Milan criteria, undergoing salvage transplantation or HCC in non-cirrhotic liver) or low risk (within Milan criteria). An estimated 255 patients per arm is expected, with the hypothesis of 5-year RFS of 60% in arm 1 and 72% in arm 2, which corresponds to a clinically relevant hazard ratio of 0.643. If the hypothesis holds true, that mTOR inhibition with SRL can improve RFS while providing adequate IS, then the standard of care regarding IS might change in the near future in patients with HCC post-LT.
Sorafenib in combination with mTORs for recurrent HCC after LT
As sorafenib is a multikinase inhibitor of Raf, vascular endothelial-and platelet-derived growth factor receptors, it mediates cell proliferation and angiogenesis, resulting in an increase in OS and improvement in radiologic progression in patients with HCC [49] . However, there is limited data regarding the concomitant use of sorafenib and mTOR inhibitors in patients post-LT with recurrent HCC [50] [51] [52] . It has been hypothesized that combination therapy could have synergistic effects [53, 54] . A recent multicenter retrospective study evaluated patients with recurrent HCC after LT who were treated with mTOR inhibitors and sorafenib during tumor relapse as patients were not candidates for locoregional therapy [55] . Two groups were assigned, with the first termed the safety population (n=31), who received sorafenib and an mTOR inhibitor for either palliative or adjuvant treatment. This group consisted of 48% of the population diagnosed with chronic hepatitis C cirrhosis with HCC, while 52% had alcoholic cirrhosis of which only 7% were found to have incidental HCC. Most underwent DDLT (93%) and were within the Milan criteria. The second population was termed the efficacy group (n=26), who received the same two drug regimen, instead for systemic treatment for tumor relapse. There were no differences in clinical parameters between the two groups. Once recurrence of HCC was confirmed, IS was switched in each patient to an mTOR inhibitor (23 patients received everolimus, 8 received SRL). Then, after stable graft function, sorafenib was added at median times of 1.1 month after everolimus initiation and 1.4 months after SRL initiation. The starting dose was 400 mg/day in the majority of patients, as the toxicity or immunologic consequences were unknown with this combination. Sorafenib was later increased to a maximum tolerated dose of 800 mg/day, and maintained until toxicity, tumor progression, hepatic decompensation or death ensued. Radiologic follow up for treatment response was conducted every 12 weeks with assessments of tumor size as well as new lesions according to the Response Evaluation Criteria in Solid Tumors [56] .
Th e overall results for dual administration of sorafenib and an mTOR inhibitor in this study were described as follows. Th e median time from LT to recurrence was 22.6 months (range 2.2-103.1 months), with nearly two-thirds (20/31) representing extrahepatic recurrence without liver involvement, about 19% having extrahepatic with hepatic recurrence, and nearly 16% having hepatic recurrence only. Th e antitumor effi cacy had an overall clinical benefi t rate of 53.8% (14/26 patients), with 3.8% (1/26) showing a partial response and the remaining 50% demonstrating disease stabilization. Patients with disease progression were seen in 38.5% (10/26), while 7.7% (2/26) could not be evaluated as sorafenib was given for <4 weeks and no imaging studies for tumor reassessment were obtained. Th e median OS aft er HCC relapse was about 40 months (95%CI 10.1-70.1 months), while the median OS since the start of the treatment with sorafenib was 19.3 months (95%CI=13.4-25.1 months). Aft er initiating sorafenib treatment, the median time to disease progression was 6.77 months (95%CI 2.3-11.1 months). Th e most common toxicities experienced in this cohort of patients were: diarrhea (77.4%), asthenia (58.1%), and handfoot syndrome (54.8%); while serious adverse events leading to death was seen in 2 patients overall: the fi rst patient experiencing uncontrolled gastric hemorrhage not related to portal hypertension or ulcer disease, and the other having a central nervous system hemorrhage 18 days aft er initiating therapy, in which treatment was stopped, however 4 weeks later the patient expired. Th e possible explanation resulting in the latter cause of bleeding was suspicion of, but unconfi rmed leptomeningeal metastases. Th ere were no recorded or suspected episodes of acute or chronic graft rejection related to mTOR inhibitors and sorafenib.
Concluding remarks
Management of patients with HCC on the waiting list vary by different institutions, however, centers that have LDLT options should consider this as an alternative for patients with HCC as the donor pool is limited and the OS and tumor recurrence rates of HCC have similar outcomes compared to DDLT. Although DFS might be worse after LDLT, discussions should be undertaken with potential donors and recipients. Changes in IS with mTORs have been studied in recurrent HCC, and the addition of sorafenib to these regimens have shown promise in improving OS and delaying disease progression. Currently, a multicenter international randomized control trial is underway to address the issue of mTOR IS ± sorafenib and recurrent HCC.
